Clinical Trial Search

Primary: Percentages of Participants by EORTC Breast Cosmetic Rating Score at 24 Months Post-radiation Therapy — 17; 26; 24; 11 Participants

Primary: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity — 50; 49 Participants

Primary: Patients With Reduction in Incidental Radiation — 46 Participants

Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR

Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants

Primary: Number of Participants Who Are Adherent to the Diet Restriction — 28 participants

Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants

Primary: Local Recurrence — 3.1 percentage of participants

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Ipsilateral Breast Tumor Recurrence-free Survival — 92 percentage of patients

Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001

Primary: Ipsilateral Recurrence Rate — 0 participants

Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells

Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants

Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage

Primary: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily — 76.0 percentage of participants

Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004

Primary: Number of Patients With Pathological Complete Response — 2 participants

Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants

Primary: Contralateral Prophylactic Mastectomy (CPM) Knowledge Assessed by Surveys for CPM-DA Participants vs. UC Participants — 62.47; 51.33 score on a scale

Primary: Number of Patients With Pathologic Complete Response (pCR) — 6 patients

Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL